Intercept Pharma Q4 Loss Widens, But Revenues Beat View - Quick Facts

(RTTNews) - Intercept Pharmaceuticals, Inc. (ICPT) reported fourth-quarter net loss of $34.82 million or $1.63 per share, wider than net loss of $12.37 million or $0.64 per share in the year-ago period.

On average, fourteen analysts polled by Thomson Reuters expected the company to report loss of $1.67 per share for the quarter. Analysts' estimates typically exclude special items.

However, licensing revenue for the quarter rose to $445 thousand from $405 thousand in the prior-year period. Analysts expected revenue of $430 thousand for the quarter.

For fiscal 2015, Intercept continues to project adjusted operating expenses in a range of $180 to $200 million, which exclude stock-based compensation and other non-cash items.